Beta2-Adrenergic receptor agonism as a therapeutic strategy for the treatment of Cushings syndrome

Kristan Cleveland,John Scott

DOI: https://doi.org/10.1124/jpet.555.963710

2024-05-15

Journal of Pharmacology and Experimental Therapeutics

Abstract:ID 96371 Poster Board 555 Cushing's syndrome is an endocrine disorder caused by chronically elevated cortisol levels. Patients often present with weight gain, chronic fatigue, and hypertension. In turn, this disorder is known to induce high blood glucose levels and changes in renal function. A-Kinase anchoring proteins (AKAPs) direct local signaling events by sequestering protein kinase A (PKA) and other signaling enzymes to defined subcellular compartments. AKAP signaling plays important roles in key cellular responses including gene transcription, ion channel regulation and hormone-mediated insulin secretion. Mutations in the catalytic subunit of PKA (PKAc) drive hypercortisolism in adrenal Cushing's syndrome. Defective local PKA signaling through AKAPs signaling has also been implicated in this endocrine disorder. Current therapies for treating Cushing's syndrome rely on surgery, radiation, or steroids to control cortisol production in the adrenal glands. Unfortunately, these therapies are either invasive, or do not completely alleviate all symptoms and comorbidities. Thus, the identification and development of new therapeutics to treat Cushing's syndrome is important. Recent studies have demonstrated that beta2-adrenergic receptor (AR) agonists can improve renal function after both acute and chronic kidney injury. Based on these findings, we investigated the relationship between Cushing's syndrome, renal function, and the effect of beta2-AR agonists on corticosterone levels in adrenal cells. Our laboratory developed the first mouse model of PKAc-derived adrenal Cushing's syndrome. The PKAc WT/W196R mouse model which expresses an adrenal specific pathogenic allele of the PKAC W196R mutant was used to characterize the kidney disease. We demonstrate that renal dysfunction in PKAc WT/W196R mice, as measured by serum creatinine and the proximal tubule-specific injury marker, kidney injury molecule-1 (KIM-1). PKAc WT/W196R mice also display elevated serum glucose levels. We used an RII overlay, or far Western Blot, to determine global PKA-RII binding as means to assess differences in AKAP expression. Global AKAP expression was increased in the renal cortex of PKAc WT/W196R compared to controls. To test the effect of beta2-AR agonists on corticosterone levels, we used wildtype PKAc, L205R, and W196R Cushing's mutants, which are characterized by elevated corticosterone. Treatment of adrenal cells expressing either PKAc L205R ot PKAc W196R with the beta2-AR agonists formoterol and salmeterol restored high corticosterone back to control levels in a concentration-dependent manner. In contrast, application of salbutamol had no effect on corticosterone levels, indicating that the property is not shared among all beta2-AR agonists. These data provide evidence that both kidney damage and altered AKAP expression are present in the kidneys of mice with Cushing's syndrome, and that the beta2-AR agonists formoterol and salmeterol decrease elevated corticosterone and may serve as potential therapies for hypercortisolism.

pharmacology & pharmacy